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Abstract
The rostromedial tegmental nucleus (RMTg) receives inputs from the laterodorsal 
tegmental and pedunculopontine tegmental nuclei, the two principle brainstem 
cholinergic nuclei.  We tested the effects of RMTg M3 and M4 muscarinic cholinergic 
receptor antagonism in a conditioned place preference (CPP) paradigm in mice.  RMTg 
infusions of the M3 muscarinic cholinergic receptor antagonist 1,1-Dimethyl-4-
diphenylacetoxypiperidinium iodide (4-DAMP) do not result in the acquisition of CPP 
but increase locomotor activation.  By contrast, RMTg infusions of the M4 muscarinic 
cholinergic receptor antagonist Tropicamide result in the acquisition of CPP but do not 
increase locomotor activation.  The rewarding effects of RMTg Tropicamide infusions 
are dopamine-dependent as systemic pre-treatment with the broad-spectrum dopamine 
receptor antagonist flupenthixol prevents the acquisition of CPP induced by RMTg 
Tropicamide infusions.  Under conditions of systemic dopamine receptor blockade, 
RMTg Tropicamide infusions significantly increase locomotor activation. These data 
provide further support for an important role of endogenous cholinergic input to the 
RMTg in reward function and suggest that the contributions of RMTg cholinergic input 
to rewarding and locomotor-activating effects involve differential contributions of RMTg 
M4 and M3 muscarinic receptors, respectively.
Keywords: laterodorsal tegmental nucleus; pedunculopontine tegmental nucleus; 
dopamine; acetylcholine; flupenthixol
Highlights
- RMTg Tropicamide but not 4-DAMP induces CPP
- RMTg 4-DAMP but not Tropicamide increases locomotion
- RMTg Tropicamide CPP is dopamine-dependent
- Flupenthixol pretreatment reveals RMTg Tropicamide locomotor effects
The laterodorsal tegmental nucleus (LDTg) and the pedunculopontine tegmental 
nucleus (PPTg) – the two principle brainstem cholinergic nuclei – each send afferents to 
the ventral tegmental area (VTA) [1-4] and specifically to dopamine (DA) neurons in this 
site [3].  GABAergic neurons in the rostromedial tegmental nucleus (RMTg; [5,6]) or, 
alternatively called the tail of the VTA [7, 8], just caudal to the classically defined VTA, 
critically control the DA system.  These GABAergic cells are continuous with those of 
the VTA, and project to [5, 6] and inhibit VTA DA neurons [9].  Similar to the VTA, the 
RMTg receives afferents from LDTg and PPTg [5, 6, 10]. Some of the LDTg/PPTg input 
to the RMTg input is cholinergic with the same LDT/PPTg cholinergic neurons sending 
collaterals to both RMTg and VTA [11].  While a role for cholinergic input to the VTA in 
reward function has been clearly established over several decades (see [12] for a review), 
the role of cholinergic input to the RMTg in reward function is less well understood. 
Previously we have shown that infusions of the M3 muscarinic receptor antagonist 1,1-
Dimethyl-4-diphenylacetoxypiperidinium iodide (4-DAMP), but not the M4 muscarinic 
receptor antagonist Tropicamide, increase drug-free and morphine-induced open-field 
locomotion in mice [13].  In the current studies we used conditioned place preference 
(CPP) – a commonly used paradigm that assesses the rewarding or aversive effects of 
drugs of abuse [14-16] – to test whether RMTg infusions of M3 or M4 muscarinic 
receptor antagonists induce rewarding effects.
To accomplish this 13 C57BL/6 mice (Charles River), maintained on a 12-hour 
light/dark cycle (lights on at 7:00 AM) with food and water available ad libitum 
throughout, were implanted with guide cannulae (26 ga; Plastics One Inc.) aimed at the 
RMTg (A-P -4.0, M-L ± 0.3, D-V – 4.3) as previously described [13, 17].  All 
experiments were performed in accordance with the guidelines outlined in the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals.  Mice were tested 
in a place conditioning apparatus consisting of two conditioning chambers (20 x 18 x 35 
cm) differing in floor texture (smooth vs. wire grid floor) and color (black vs. black with 
vertical white stripes) connected by a third chamber (20 x 10 x 35 cm).  The position of 
the mouse within the apparatus was monitored via a dedicated camera mounted above 
each apparatus and video tracking software (ANY-Maze; Stoelting Co.; Wood Dale, IL).  
ANY-Maze was used to measure time spent, and distance traveled in each of the 
chambers.  All mice received an initial 30 min habituation session in which mice had free 
access to the entire apparatus.  After 2-4 days baseline preferences for the two 
conditioning chambers were determined during a 20 min session in which mice had free 
access to the entire apparatus.  We used a biased conditioning procedure in which the 
initially less preferred chamber was subsequently paired with RMTg infusions of either 
10.32 μg Tropicamide or 2 μg 1,1-Dimethyl-4-diphenylacetoxypiperidinium iodide (4-
DAMP; Tocris Bioscience), each dissolved in 0.05% DMSO (these doses were 
previously tested for their locomotor effects in RMTg [13]) and the alternate chamber 
was paired with RMTg vehicle infusion (4 alternating pairings of each).  All intracranial 
infusions (injector cannulae 2 mm longer than guide cannulae) were made at a volume of 
0.3 μl and at rate of 0.2 μl/min and mice were immediately confined to their respective 
conditioning chamber for a period of 30 min.  During the subsequent CPP test, on the day 
following the 8th conditioning session, mice were again given free access to the entire 
apparatus.  Following completion of behavioral testing mice were transcardially perfused 
and coronal cryosections throughout the extent of the RMTg were stained with cresyl 
violet to verify injection sites.  Mice that did not have bilateral RMTg infusion sites were 
excluded from statistical analysis (2 for the Tropicamide and 1 for 4-DAMP CPP 
experiments).  A difference score (time spent in the chamber during the CPP test – time 
spent in the chamber during the baseline test) was computed for each mouse.  Total 
distance traveled while mice were confined to conditioning chambers was also measured.  
All data were analyzed using single-sample or paired-samples t-tests. 
Infusions of the M3 muscarinic receptor antagonist 4-DAMP into RMTg sites (between 
Bregma -4.04 to – 4.28 [Fig 1A]) did not lead to the acquisition of conditioned place preference 
(paired-samples t-test comparing difference scores for 4-DAMP and vehicle chambers: t4 = 0.4, p 
> 0.1; single-sample t-test comparing the mean difference score for the 4-DAMP chamber to 0: t4 
= - 1.45, p > 0.1 [Fig 1B]).  By contrast, infusions of the M4 muscarinic receptor antagonist 
Tropicamide into RMTg sites (between Bregma -4.04 and -4.16 [Fig 2A, asterisk symbols]) did 
lead to the acquisition of conditioned place preference (paired-samples t-test comparing 
difference scores for Tropicamide and vehicle chambers: t4 = 3.19, p < 0.05; single-sample t-test 
comparing the mean difference score for the Tropicamide chamber to 0: t4 = 3.12, p < 0.05 [Fig 
2B]).  We also measured the total distance traveled while mice were confined to the conditioning 
chambers and computed the average total distance traveled across 4 vehicle and 4 antagonist (4-
DAMP or Tropicamide) conditioning sessions.  Consistent with our previous report [13] RMTg 
infusions of 4-DAMP [Fig 1C] but not RMTg infusions of Tropicamide [Fig 2C] increased 
locomotion relative to RMTg vehicle infusions (4-DAMP paired-samples t-test: t19 = 3.12, p < 
0.01; Tropicamide paired-samples t-test: t19 = 0.24, p > 0.1).  Thus RMTg antagonism of M3 or 
M4 muscarinic receptors, each of which are found in the RMTg [18], has opposite effects.  
RMTg 4-DAMP infusions do not result in the acquisition of CPP but increase locomotion, while 
RMTg Tropicamide infusions result in the acquisition of CPP but do not significantly affect 
locomotion.  These data provide further support for an important role of endogenous cholinergic 
input to the RMTg, likely originating from the LDTg/PPTg, in reward function.  More 
importantly, the contributions of cholinergic input to rewarding and locomotor-activating effects 
involve differential contributions of RMTg M4 and M3 muscarinic receptors, respectively.  
We next assessed whether the acquisition of CPP induced by RMTg Tropicamide 
infusions is dopamine-dependent.  In an additional group of mice (n = 8, final statistical analysis 
based on n = 6) we tested whether RMTg Tropicamide infusions induce CPP under conditions of 
systemic dopamine receptor blockade. For these experiments mice were given a systemic 
injection of the broad-spectrum dopamine receptor antagonist flupenthixol (0.08 mg/kg, i.p.) 1 
hour prior to each of the four RMTg Tropicamide infusion conditioning days. On RMTg vehicle 
infusion conditioning days mice received a saline injection (10 ml/kg i.p.) 1 hour prior to the 
intracranial injection.  Under conditions of systemic dopamine receptor blockade, RMTg 
infusions of Tropicamide did not lead to the acquisition of CPP (paired-samples t-test comparing 
difference scores for Tropicamide and vehicle chambers: t5 = 2.24, p > 0.05; single-sample t-test 
comparing the mean difference score for the Tropicamide chamber to 0: t5 = 1.34, p > 0.1 [Fig 
2D]).  Importantly, we also tested whether the dose of flupenthixol used has any motivational 
effects on its own in a separate group of mice (n =8; final statistical analysis based on n = 7 as 
one mouse died during the experiment).  For these CPP studies we also employed a biased 
conditioning procedure but paired systemic flupenthixol treatment with the initially more 
preferred chamber.  Mice received a systemic injection of either flupenthixol (0.08 mg/kg, i.p.) 
or saline (10 ml/kg, i.p.) 1 hour prior to being confined to their respective conditioning chamber 
for a period of 30 min.  Flupenthixol by itself did not result in the acquisition of either CPP or a 
conditioned place aversion (paired-samples t-test comparing difference scores for flupenthixol 
and saline chambers: t6 = 2.09, p > 0.05; single-sample t-test comparing the mean difference 
score for the Flupenthixol chamber to 0: t6 = 1.52, p > 0.1 [Fig 2F]).  By contrast, following 
flupenthixol pretreatment, RMTg infusions of Tropicamide increased locomotion relative to 
RMTg vehicle infusions following saline pretreatment (paired-samples t-test: t23 = 11.86 p < 
0.00001[Fig 2E]). The dose of flupenthixol used did not significantly affect locomotion on its 
own (paired-samples t-test: t27 = 1.31, p > 0.1 [Fig 2G]). Thus, the rewarding effects of RMTg 
M4 muscarinic receptor antagonism require intact dopamine signaling as flupenthixol 
pretreatment blocks the acquisition of CPP. At the same time, however, intact dopamine 
signaling appears to oppose the potential locomotor activating effects of RMTg M4 muscarinic 
receptor antagonism.  The locomotor activating effects of RMTg Tropicamide infusions are only 
revealed under these conditions. 
To summarize, first, we show that endogenous cholinergic input to the RMTg, mediated 
through M4 muscarinic, but not M3 muscarinic, receptors contributes to reward.  Second, we 
provide additional support for the importance of cholinergic input to the RMTg in modulating 
locomotor activation [11, 13].  However, endogenous cholinergic input to the RMTg appears to 
differentially contribute to reward and locomotion through M4 and M3 muscarinic cholinergic 
receptors, respectively.  Dissociations of rewarding and locomotor effects are not without 
precedent.  In the rat VTA, for example, it has been shown that the locomotor-activating and 
rewarding effects of opioids can be dissociated, with AMPA glutamate receptor antagonists 
infused into the anterior or posterior portions of the VTA differentially affecting the rewarding 
and locomotor-activating effects of opiates, respectively [19]. Our data suggest that rewarding 
and locomotor-activating effects are dissociable in RMTg as well, but according to muscarinic 
receptor subtype. To our knowledge, this is the first such report in the RMTg.  Whether this 
correlates with differential distribution of M3 and M4 muscarinic receptors within the RMTg 
remains to be determined. 
In our experiments we measured locomotor activity during each of the conditioning 
sessions while mice were confined to a conditioning chamber. Previously we investigated the 
effects of RMTg 4-DAMP or Tropicamide infusions on open-field locomotion [13].  While the 
two testing conditions differ in obvious ways (i.e. chamber size, tactile and visual features of the 
chambers), the current data are consistent with and extend our previous report [13] that RMTg 4-
DAMP, but not Tropicamide, infusions increase locomotor activation.  Here we show that 
dopamine signaling contributes to RMTg Tropicamide locomotion as well, at least within the 
confines of the CPP apparatus conditioning chambers.  The fact that RMTg Tropicamide only 
increased locomotion when dopamine receptor signaling was blocked suggests two thing.  First, 
M4-mediated cholinergic signaling in RMTg modulates midbrain dopamine signaling and, 
second, its effects on dopamine signaling normally result in an inhibition of locomotion.  
Importantly, flupenthixol had no effects on locomotion by itself.
Whether M3 or M4 receptors found in the RMTg [18] are associated with GABA neurons 
or with the axon terminals of RMTg afferents is not clear.  In the VTA, M3 receptors are 
associated with GABAergic neurons, while M4 receptors have been associated with LDTg/PPTg 
cholinergic terminals [20, 21]. If a similar arrangement exists in RMTg, and excitatory M3 
receptors are associated with RMTg GABAergic cell bodies, then endogenous cholinergic input 
should increase RMTg GABAergic inhibition of VTA dopamine neurons.  RMTg M3 receptor 
blockade then would increase locomotion by reducing GABAergic inhibition of VTA dopamine 
neurons.  While we demonstrate this, the fact that this does not result in concurrent rewarding 
effects, as demonstrated by the lack of CPP acquisition following RMTg 4-DAMP infusions, is 
surprising.  
The lack of a locomotor effect of RMTg Tropicamide infusions shown previously [13], 
and replicated here, has been interpreted [12] in light of the assumption that M4 receptors are 
associated with RMTg cholinergic afferents (from LDTg and/or PPTg) where they may act as 
inhibitory presynaptic autoreceptors, similar to what has been shown in the VTA [21]. RMTg 
Tropicamide infusions would then result in an accumulation of RMTg acetylcholine levels by 
blockade of the inhibitory presynaptic autoreceptor.  In turn, this would result in increased 
cholinergic excitation of RMTg GABA neurons, possibly, via M3 receptors and consequently 
increased inhibition of midbrain dopamine neurons. Alternatively, if inhibitory M4 receptors are 
associated with RMTg GABA cell bodies then endogenous cholinergic input should inhibit 
RMTg GABA neurons and consequently decrease inhibition of midbrain dopamine neurons. 
RMTg Tropicamide infusions would then result in decreased cholinergic inhibition of RMTg 
GABA neurons and consequently increased inhibition of midbrain dopamine neurons. The 
dopamine-dependent rewarding effects of RMTg Tropicamide infusions, however, are not easily 
reconciled with either of these interpretations.  Our data thus point to a need for a better 
understanding of where RMTg M3 and M4 muscarinic receptors are located.  This will require 
detailed analysis at the level of electron microscopy.  Furthermore, electrophysiological studies 
investigating the effects of RMTg 4-DAMP or Tropicamide application on RMTg GABA or 
VTA dopamine neuron activity are also lacking.  Finally, while the VTA is a major projection 
target, the RMTg also projects to other brainstem targets, notably the LDTg/PPTg and the dorsal 
raphe [6]. The LDTg/PPTg (for a review see [12]) and the dorsal raphe [22, 23], in turn, each 
modulate the activity of midbrain dopamine neurons and reward related behavior.  This raises the 
possibility that cholinergic modulation of RMTg GABA neurons may indirectly modulate 
dopamine signaling through these sites. Identification of the projection targets of RMTg GABA 
neurons receiving cholinergic input would be informative in this regard.  The interpretation of 
the rewarding and locomotor activating effects of RMTg 4-DAMP or Tropicamide infusions will 
clearly be greatly facilitated by the aforementioned studies. 
In conclusion, we show that locomotor and rewarding effects of endogenous cholinergic 
inputs to the RMTg are dissociable. M3 and M4 muscarinic receptor signaling in RMTg 
differentially contributes to locomotor activation and reward, respectively.
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Figure 1. RMTg infusions of the M3 muscarinic receptor antagonist 4-DAMP 
increase locomotor activation but do not lead to the acquisition of conditioned place 
preference 
A. Bilateral RMTg injection sites for mice used in 4-DAMP CPP studies (n = 5).  B. 
RMTg 4-DAMP infusions do not lead to the acquisition of conditioned place preference. 
C. By contrast, in the same mice locomotor activity measured within the RMTg 4-DAMP 
infusion conditioning chamber is significantly greater than locomotor activity measured 
within the RMTg vehicle infusion conditioning chamber (** p < 0.01 [4-DAMP vs. 
vehicle conditioning chambers]). All error bars represent ±SEM.
Figure 2. RMTg infusions of the M4 muscarinic receptor antagonist Tropicamide 
lead to the acquisition of conditioned place preference but do not increase locomotor 
activation 
A. Bilateral RMTg injection sites for mice used in Tropicamide CPP studies (n = 5; 
asterisk symbols) and for mice used in Tropicamide CPP studies involving concurrent 
systemic pharmacological blockade of dopamine signaling (n = 6; solid circles). B. 
RMTg Tropicamide infusions result in the acquisition of conditioned place preference (* 
p < 0.05 [single-sample t-test: Tropicamide chamber difference score vs. 0]). C. By 
contrast, in the same mice locomotor activity measured within RMTg Tropicamide 
infusion and RMTg vehicle infusion conditioning chambers did not differ. D.  Systemic 
pretreatment with the broad-spectrum dopamine receptor antagonist flupenthixol (0.08 
mg/kg, i.p., given 1 hr prior to RMTg Tropicamide infusion conditioning sessions) 
prevents the acquisition of CPP induced by RMTg Tropicamide infusions (n = 6).  E. By 
contrast, in the same mice locomotor activity measured within the RMTg Tropicamide 
infusion conditioning chamber following flupenthixol pre-treatment was significantly 
greater than locomotor activity measured within the RMTg vehicle infusions conditioning 
chamber following saline pre-treatment (** p < 0.01 [flupenthixol/Tropicamide vs. 
saline/vehicle chamber]). F. The dose of systemic flupenthixol used has no motivational 
effects on its own. Neither conditioned place preference nor conditioned place aversion 
are observed in mice (n = 7).  G. Locomotor activity measured within the flupenthixol 
and saline conditioning chamber does not differ. All error bars represent ±SEM.


